Breaking News
Subscribe Now 0
Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 place See list

Stock Markets Analysis & Opinion

Contribute
Modest Money
Is CorMedix Overvalued? By Modest Money - Apr 02, 2019

CorMedix Inc. (NYSE:CRMD) is a commercial-stage pharmaceutical company focused on harnessing its taurolidine technology for the prevention and treatment of infectious and inflammatory diseases. The...

Alex Newman
Genfit IPO Starts Well: Long-Term Uncertain By Alex Newman - Apr 02, 2019

Biotech firm Genfit (NASDAQ:GNFT) ran the NASDAQ bell on Wednesday, and the company had a solid debut as it went public. The NASDAQ reported that Genfit closed Tuesday’s trading to $22.17, a...

Guy S. Ortmann, CMT
Indexes May Surprise On Upside By Guy S. Ortmann, CMT - Apr 02, 2019

Charts Positive As SPX Estimates PopOn the charts, all of the indexes closed higher Monday with positive internals on the NYSE and NASDAQ as volumes declined from the prior session. Several of the...

Continue with Apple
Continue with Google
or
Sign up with Email